Keep up with our latest news, and connect with us on social media.


Epic Bio Announces Presentations at Upcoming Scientific and Medical Conferences

SOUTH SAN FRANCISCO, Calif. — March 6, 2023 — Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced presentations at two upcoming scientific and medical conferences.

Keystone Symposia: Chromatin Architecture in Development and Human Health
Poster Title: Discovery and engineering of hypercompact transcriptional modulators
for robust and durable target gene activation
Date & Time: Monday, March 13, 7:30 p.m. PT
Poster Number: 1507 (Session 1)
Location: Fairmont Empress Victoria Conference Center, British Columbia, Canada

MDA (Muscular Dystrophy Association) Clinical & Scientific Conference
Oral Presentation Title: EPI-321, a Potential Cure for FSHD
Date & Time: Wednesday, March 22, 10:15 a.m. CT
Location: Hilton Anatole, Dallas, Texas

About Epic Bio
Epic Bio is a leading epigenome engineering company, leveraging the power of CRISPR without cutting DNA. The company is using its proprietary Gene Expression Modulation System (GEMS) to develop therapies. Through the company’s library of the most compact Cas DNA-binding proteins to work on human cells, the company is developing in vivo therapies with delivery via a single AAV vector. Epic Bio has an initial focus on Facioscapulohumeral Muscular Dystrophy (FSHD) and is conducting additional research to address Antitrypsin Deficiency (A1AD), Heterozygous Familial Hypercholesterolemia (HeFH), as well as other indications. The company is financially backed by Horizons Ventures and other leading investors. Visit for more information or follow us on Twitter and LinkedIn.

Investor Contact

Shawn M. Cox
Epic Bio
Manager, Investor Relations, Corporate Communications

Media Contact

Lisa Raffensperger
Ten Bridge Communications
(617) 903-8783

The latest from Epic

16 Nov

"The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to EPI-321 for the treatment of facioscapulohumeral muscular dystrophy (FSHD), the most common form of muscular dystrophy in adults. Read more here: "

7 Nov

"We are pleased to share that Epic Bio CEO Dr. Amber Salzman has been invited to present at the 2023 Stiefel Healthcare Conference. Read more here: "

31 Oct

"@Epicbiotech partners with @KitePharma to extend the potential application of Epic’s platform for cancer treatment. Epic’s approach is promising for in vivo medicines and may enable next-generation cell therapies #epigenetics #CellTherapy #Cancer "